Demographic and clinical features of MIS-C cohort
| . | MIS-C (n = 154) . | MIS-C with BTNL8 variants (n = 9) . | MIS-C with IEI variants (n = 6) . |
|---|---|---|---|
| Demographics | n (%) | n (%) | n (%) |
| Sex, males | 88 (57.1) | 4 (44.4) | 6 (100) |
| Age, years, median (IQR)a | 9 (5–12) | 10 (6–12) | 7 (6–10) |
| Comorbidities | 51 (33.1) | 2 (22.2) | 2 (33.3) |
| Genetically predicted ancestry | |||
| AMR | 45 (29.2) | 2 (22.2) | 1 (16.7) |
| AFR | 41 (26.6) | 3 (3.3) | 3 (50) |
| EUR | 40 (26.0) | 3 (3.3) | 1 (16.7) |
| SAS | 18 (11.7) | 1 (11.1) | 0 |
| EAS | 5 (3.2) | 0 (0) | 1 (16.7) |
| Unknown | 5 (3.2) | 0 (0) | 0 |
| Association with SARS-CoV-2 | |||
| PCR positive | 21 (13.6) | 1 (11.1) | 0 (0) |
| Serology positive | 125 (81.2) | 6 (66.7) | 6 (100) |
| Serology unknown | 13 (8.4) | 2 (22.2) | 0 (0) |
| Presenting symptoms | |||
| Fever | 154 (100) | 9 (100) | 6 (100) |
| GI | 122 (79.2) | 9 (100) | 6 (100) |
| Conjunctivitis | 99 (64.3) | 8 (88.9) | 5 (83.3) |
| Rash | 87 (56.5) | 6 (66.7) | 5 (83.3) |
| Systemic shock | 46 (29.9) | 4 (44.4) | 2 (33.3) |
| Cardiovascular | 45 (29.2) | 2 (22.2) | 1 (16.7) |
| Lymphadenopathy | 26 (16.9) | 1 (11.1) | 0 (0) |
| Inflamed extremities | 21 (13.6) | 2 (22.2) | 2 (33.3) |
| Respiratory | 16 (10.4) | 0 (0) | 0 (0) |
| Mucositis | 14 (9.1) | 0 (0) | 0 (0) |
| Severity | |||
| ICU | 98 (63.6) | 5 (55.6) | 4 (66.7) |
| Death | 1 (0.6) | 0 (0) | 0 (0) |
| . | MIS-C (n = 154) . | MIS-C with BTNL8 variants (n = 9) . | MIS-C with IEI variants (n = 6) . |
|---|---|---|---|
| Demographics | n (%) | n (%) | n (%) |
| Sex, males | 88 (57.1) | 4 (44.4) | 6 (100) |
| Age, years, median (IQR)a | 9 (5–12) | 10 (6–12) | 7 (6–10) |
| Comorbidities | 51 (33.1) | 2 (22.2) | 2 (33.3) |
| Genetically predicted ancestry | |||
| AMR | 45 (29.2) | 2 (22.2) | 1 (16.7) |
| AFR | 41 (26.6) | 3 (3.3) | 3 (50) |
| EUR | 40 (26.0) | 3 (3.3) | 1 (16.7) |
| SAS | 18 (11.7) | 1 (11.1) | 0 |
| EAS | 5 (3.2) | 0 (0) | 1 (16.7) |
| Unknown | 5 (3.2) | 0 (0) | 0 |
| Association with SARS-CoV-2 | |||
| PCR positive | 21 (13.6) | 1 (11.1) | 0 (0) |
| Serology positive | 125 (81.2) | 6 (66.7) | 6 (100) |
| Serology unknown | 13 (8.4) | 2 (22.2) | 0 (0) |
| Presenting symptoms | |||
| Fever | 154 (100) | 9 (100) | 6 (100) |
| GI | 122 (79.2) | 9 (100) | 6 (100) |
| Conjunctivitis | 99 (64.3) | 8 (88.9) | 5 (83.3) |
| Rash | 87 (56.5) | 6 (66.7) | 5 (83.3) |
| Systemic shock | 46 (29.9) | 4 (44.4) | 2 (33.3) |
| Cardiovascular | 45 (29.2) | 2 (22.2) | 1 (16.7) |
| Lymphadenopathy | 26 (16.9) | 1 (11.1) | 0 (0) |
| Inflamed extremities | 21 (13.6) | 2 (22.2) | 2 (33.3) |
| Respiratory | 16 (10.4) | 0 (0) | 0 (0) |
| Mucositis | 14 (9.1) | 0 (0) | 0 (0) |
| Severity | |||
| ICU | 98 (63.6) | 5 (55.6) | 4 (66.7) |
| Death | 1 (0.6) | 0 (0) | 0 (0) |
IQR, Interquartile range.